CBER director Peter Marks believes recent safety issues with gene therapy products are merely speed bumps and overcoming them will advance the science. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
